Ind-Swift Labs.

Why is Ind-Swift Laboratories Ltd falling/rising?

As of 06-Aug, Ind-Swift Laboratories Ltd's stock price is at 226.25, down 1.99% after a trend reversal following four days of gains, with decreased investor participation and short-term weakness indicated by moving averages.

As of 06-Aug, Ind-Swift Laboratories Ltd's stock price is falling, currently at 226.25, which reflects a decrease of 4.6 or 1.99%. This decline follows a trend reversal after four consecutive days of gains. The stock has underperformed its sector by 2.49% today and reached an intraday low of Rs 225.1. Additionally, there has been a significant drop in investor participation, with delivery volume falling by 42.74% compared to the 5-day average. Although the stock remains above the 50-day, 100-day, and 200-day moving averages, it is currently below the 5-day and 20-day moving averages, indicating a short-term weakness. Overall, these factors contribute to the stock's current downward movement.

Which are the latest news on Ind-Swift Labs.?

When is the next results date for Ind-Swift Laboratories Ltd?

The next results date for Ind-Swift Laboratories Ltd is 10 August 2026.

The next results date for Ind-Swift Laboratories Ltd is scheduled for 10 August 2026.

How big is Ind-Swift Labs.?

As of 10th June, Ind-Swift Laboratories Ltd has a market capitalization of 1,452.00 Cr, classifying it as a Micro Cap company, with recent net sales of 626.01 Cr and a net profit of 41.41 Cr.

As of 10th June, Ind-Swift Laboratories Ltd has a market capitalization of 1,452.00 Cr, which classifies it as a Micro Cap company.<BR><BR>In the latest four quarters, the company reported Net Sales of 626.01 Cr and a Net Profit of 41.41 Cr.<BR><BR>The latest annual period for the balance sheet is March 2025, with Shareholder's Funds amounting to 1,173.00 Cr and Total Assets of 1,393.70 Cr.

Who are in the management team of Ind-Swift Labs.?

The management team of Ind-Swift Labs includes N R Munjal (Chairman & Managing Director), Himanshu Jain (Joint Managing Director), and several executive directors, along with independent directors such as Prabhat Khurana and S P Sharma, providing strong leadership and governance.

The management team of Ind-Swift Labs includes the following individuals:<BR><BR>1. N R Munjal - Chairman & Managing Director<BR>2. N R Munjal - Vice Chairman & Managing Director<BR>3. Himanshu Jain - Joint Managing Director<BR>4. Pradeep Verma - Company Secretary<BR>5. Rishav Mehta - Executive Director<BR>6. Sahil Munjal - Executive Director<BR><BR>Additionally, the board features several independent directors:<BR><BR>1. Prabhat Khurana - Independent Director<BR>2. S P Sharma - Independent Director<BR>3. Neerja Chathley - Independent Director<BR>4. Ashwani K Vig - Independent Director<BR>5. Rajendra Kumar Gupta - Independent Director<BR><BR>This team brings a mix of leadership and governance to the company.

Who are the peers of the Ind-Swift Labs.?

Ind-Swift Labs. peers include NGL Fine Chem, Hester Bios, Windlas Biotech, Amrutanjan Healt, Shukra Pharma, Jagsonpal Pharma, Syncom Formul., Lincoln Pharma, and Fredun Pharma. Ind-Swift Labs. has below-average management risk and a 1-year return of 46.22%, lower than Fredun Pharma's 211.49% but higher than Windlas Biotech's -12.26%.

Peers: The peers of Ind-Swift Labs. are NGL Fine Chem, Hester Bios, Windlas Biotech, Amrutanjan Healt, Shukra Pharma., Jagsonpal Pharma, Syncom Formul., Lincoln Pharma., and Fredun Pharma.<BR><BR>Quality Snapshot: Excellent management risk is observed at Shukra Pharma., Amrutanjan Healt, Windlas Biotech, and the rest. Average management risk is found at NGL Fine Chem, Hester Bios, Jagsonpal Pharma, Syncom Formul., Lincoln Pharma, and Fredun Pharma. Below Average management risk is attributed to Ind-Swift Labs. Growth is Excellent at Shukra Pharma. and Fredun Pharma, while Below Average growth is noted at NGL Fine Chem, Hester Bios, Windlas Biotech, Amrutanjan Healt, Ind-Swift Labs., Jagsonpal Pharma, Syncom Formul., Lincoln Pharma, and the rest.<BR><BR>Return Snapshot: The peer with the highest 1-year return is Fredun Pharma at 211.49%, while Windlas Biotech has the lowest at -12.26%. Ind-Swift Labs. has a 1-year return of 46.22%, which is significantly higher than Windlas Biotech but lower than Fredun Pharma. Additionally, Amrutanjan Healt, Windlas Biotech, and Syncom Formul. have negative six-month returns.

What does Ind-Swift Labs. do?

Ind-Swift Laboratories Ltd is a micro-cap company based in Chandigarh, India, specializing in the manufacture of active pharmaceutical ingredients (APIs). As of March 2026, it reported net sales of 170 Cr and a net profit of 15 Cr.

Overview:<BR>Ind-Swift Laboratories Ltd is a leading manufacturer of active pharmaceutical ingredients (APIs) in the Pharmaceuticals & Biotechnology industry, categorized as a Micro Cap company.<BR><BR>History:<BR>Ind-Swift Laboratories Ltd is part of the Ind-Swift Group and is based in Chandigarh, India. The company operates two advanced manufacturing facilities and adheres to international standards. The latest quarterly results reported net sales and net profit for the period ending March 2026.<BR><BR>Financial Snapshot:<BR>- Net Sales: 170 Cr (Quarterly Results - Mar 2026)<BR>- Net Profit: 15 Cr (Quarterly Results - Mar 2026)<BR>- Market Cap: INR 1,452 Cr (Micro Cap)<BR><BR>Key Metrics:<BR>- P/E: 29.00<BR>- Industry P/E: 34<BR>- Dividend Yield: 0.00%<BR>- Debt Equity: -0.31<BR>- Return on Equity: 3.61%<BR>- Price to Book: 1.03<BR><BR>Contact Details:<BR>- Address: SCO 850 Shivalik Enclave, NAC Manimajra Chandigarh Chandigarh (U T): 160101<BR>- Tel: 91-0172-5061850/2730920<BR>- Email: investor@indswiftlabs.com<BR>- Website: http://www.indswiftlabs.com

Should I buy, sell or hold Ind-Swift Laboratories Ltd?

Are Ind-Swift Laboratories Ltd latest results good or bad?

Ind-Swift Laboratories Ltd's latest results show strong quarterly revenue growth and improved operating margins, but a concerning 93.20% year-on-year net profit decline and negative long-term growth rates indicate structural challenges. While short-term performance is positive, the long-term outlook remains uncertain.

Ind-Swift Laboratories Ltd's latest results indicate a mixed performance. On the positive side, the company reported robust revenue growth, with net sales reaching ₹169.79 crores, marking a 12.56% increase sequentially and a 22.82% increase year-on-year. This is the highest quarterly sales figure in recent periods, suggesting a strengthening demand for its API products.<BR><BR>Moreover, the company achieved a net profit of ₹15.11 crores, which reflects a significant quarter-on-quarter increase of 58.39%. The operating margin also improved to 12.12%, the best in seven quarters, indicating enhanced operational efficiency.<BR><BR>However, there are notable concerns. The year-on-year net profit decline of 93.20% is alarming, primarily due to extraordinary items that inflated profits in the previous year. Additionally, the company's long-term growth trajectory remains weak, with a five-year sales growth rate of negative 7.04% and EBIT growth of negative 179.30%. This suggests structural challenges that could hinder sustained profitability.<BR><BR>Overall, while the recent quarterly results show tactical improvements, the long-term outlook remains uncertain due to these ongoing challenges. Investors should weigh the positive short-term performance against the backdrop of significant long-term risks.

Is Ind-Swift Labs. technically bullish or bearish?

As of November 17, 2025, the technical trend has shifted to mildly bearish due to bearish momentum indicated by MACD readings and Bollinger Bands, despite some mixed signals from moving averages and Dow Theory.

As of 17 November 2025, the technical trend has changed from mildly bullish to mildly bearish. The current technical stance is mildly bearish, driven by weekly and monthly MACD readings indicating bearish momentum, along with Bollinger Bands signaling bearish conditions. The KST also reflects a mildly bearish outlook on the weekly and bearish on the monthly. Although the daily moving averages show a mildly bullish trend, the overall indicators suggest weakness. The Dow Theory presents a mixed view with a mildly bearish weekly stance and a mildly bullish monthly stance, adding to the uncertainty. The stock has underperformed against the Sensex across multiple time frames, further supporting the bearish sentiment.

How has been the historical performance of Ind-Swift Labs.?

Ind-Swift Labs has faced significant financial volatility, with net sales dropping from INR 1,709.15 crore in March 2024 to INR 561.71 crore in March 2025, resulting in an operating loss of INR 19.39 crore. Despite a positive profit before tax of INR 257.80 crore in March 2025, overall performance reflects ongoing operational challenges.

Answer:<BR>The historical performance of Ind-Swift Labs shows significant fluctuations in key financial metrics over the years.<BR><BR>Breakdown:<BR>Ind-Swift Labs experienced a notable decline in net sales from INR 1,709.15 crore in March 2024 to INR 561.71 crore in March 2025, following a peak of INR 1,207.31 crore in March 2023. The total operating income mirrored this trend, dropping to INR 561.71 crore in March 2025 from INR 1,709.15 crore in the previous year. The company's operating profit (PBDIT) also fell sharply, resulting in a loss of INR 19.39 crore in March 2025, compared to a profit of INR 303.06 crore in March 2024. Despite these challenges, profit before tax remained positive at INR 257.80 crore in March 2025, although it decreased from INR 598.22 crore in March 2024. The profit after tax for March 2025 was INR 250.53 crore, down from INR 539.24 crore the previous year. On the balance sheet, total liabilities slightly decreased to INR 1,393.70 crore in March 2025 from INR 1,409.22 crore in March 2024, while total assets also saw a minor decline to INR 1,393.70 crore. Cash flow from operating activities was negative at INR -25.00 crore in March 2025, reflecting ongoing operational challenges. Overall, the financial performance of Ind-Swift Labs indicates a period of significant volatility and operational difficulties in the most recent fiscal year.

Is Ind-Swift Labs. overvalued or undervalued?

As of August 12, 2025, Ind-Swift Labs. is considered risky and overvalued with a PE ratio of 59.73, a negative EV to EBITDA of -5.91, and a significant decline of 39.74% over the past year, contrasting sharply with its peers Sun Pharma and Cipla, which have lower PE ratios and are deemed attractive.

As of 12 August 2025, the valuation grade for Ind-Swift Labs. has moved from attractive to risky, indicating a significant shift in its perceived value. The company is currently considered overvalued, with a PE ratio of 59.73, an EV to EBITDA of -5.91, and a PEG ratio of 0.00, which suggests that the stock may not be justified by its earnings growth potential. <BR><BR>In comparison to its peers, Ind-Swift Labs. has a much higher PE ratio than Sun Pharma (33.93) and Cipla (22.77), both of which are categorized as attractive. Additionally, the company's negative EV to EBITDA ratio raises concerns about its operational profitability relative to its enterprise value. While Ind-Swift Labs. has shown strong returns over the long term, its recent performance has lagged behind the Sensex, particularly over the past year, where it has declined by 39.74% compared to a modest 0.74% gain in the index.

Who are the top shareholders of the Ind-Swift Labs.?

The top shareholders of Ind-Swift Labs include Essix Biosciences Limited with 36.83%, Wilson Holdings Private Limited at 8.72%, and individual investors holding 37.61%. Additionally, 7 Foreign Institutional Investors own 3.07%, with no pledged promoter holdings or mutual funds involved.

The top shareholders of Ind-Swift Labs include Essix Biosciences Limited, which holds the largest share at 36.83%. Following that, Wilson Holdings Private Limited is the highest public shareholder with an ownership stake of 8.72%. Additionally, individual investors collectively hold 37.61% of the company's shares. The company also has 7 Foreign Institutional Investors (FIIs) holding a total of 3.07%. There are no pledged promoter holdings and no mutual funds currently holding shares in the company.

Has Ind-Swift Labs. declared dividend?

Ind-Swift Laboratories Ltd has declared a 10% dividend, amounting to 1 per share, with an ex-date of September 20, 2011. However, the dividend yield is 0%, and total returns have varied significantly, showing strong long-term performance despite recent declines.

Ind-Swift Laboratories Ltd has declared a 10% dividend.<BR><BR>Dividend Details:<BR>- Percentage announced: 10%<BR>- Amount per share: 1 per share<BR>- Ex-date: 20 Sep 11<BR><BR>Dividend Yield: 0%<BR><BR>Total Returns by Period:<BR>In the last 6 months, the price return was -15.31%, with a dividend return of 0%, resulting in a total return of -15.31%.<BR><BR>Over the past year, the price return was -14.71%, and with a dividend return of 0%, the total return was -14.71%.<BR><BR>In the 2-year period, the price return was 30.56%, with a dividend return of 0%, leading to a total return of 30.56%.<BR><BR>For the 3-year period, the price return was 56.82%, while the dividend return remained 0%, resulting in a total return of 56.82%.<BR><BR>In the 4-year period, the price return was 8.6%, with a dividend return of 0%, giving a total return of 8.6%.<BR><BR>Lastly, over the 5-year period, the price return was 234.33%, and the dividend return was 0%, resulting in a total return of 234.33%.<BR><BR>Overall, while Ind-Swift Laboratories Ltd has declared a dividend, the dividend yield is 0%, indicating that the dividend has not contributed to returns in recent periods. The total returns show significant variability, with strong performance over the longer term despite recent declines in price returns.